Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
14.00
-0.32 (-2.23%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for TRDA stock have an average target of 21, with a low estimate of 20 and a high estimate of 22. The average target predicts an increase of 50.00% from the current stock price of 14.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2024.
Analyst Ratings
The average analyst rating for TRDA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +42.86% | Mar 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $22 | Buy | Initiates | $22 | +57.14% | Jan 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +42.86% | Nov 27, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +78.57% | Sep 22, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +78.57% | Aug 9, 2023 |
Financial Forecast
Revenue This Year
142.35M
from 129.01M
Increased by 10.34%
Revenue Next Year
58.25M
from 142.35M
Decreased by -59.08%
EPS This Year
-0.52
from -0.20
EPS Next Year
-3.73
from -0.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 157.5M | 78.8M | 78.8M | n/a | 640.0M |
| Avg | 142.4M | 58.2M | 61.3M | n/a | 310.9M |
| Low | 131.4M | 47.0M | 48.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.1% | -44.7% | 35.2% | - | - |
| Avg | 10.3% | -59.1% | 5.3% | - | - |
| Low | 1.9% | -67.0% | -17.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.28 | -2.32 | -2.95 | -4.45 | 6.36 |
| Avg | -0.52 | -3.73 | -3.54 | -4.32 | 6.18 |
| Low | -0.78 | -4.38 | -4.31 | -4.16 | 5.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.